Treating abnormal uterine bleeding in e.g. metrorrhagia

摘要

Treatment of abnormal uterine bleeding comprises admin. of a competitive progesterone antagonist (I). Pref. (I) include 11 beta -(4-N,N-dimethylamino) -phenyl)-17 beta -hydroxy -17 alpha -propynyl- 4,9(10)-oestradiene-3-one (RU 38486) (IA); 11 beta -((4-N,N- dimethylamino)-phenyl) -17 beta -hydroxy-18-methyl -17 alpha -propynyl- 4,9(10) -oestradien-3-one (IB); 11 beta -((4-N,N-dimethylamino)- phenyl)-17a - beta -hydroxy 17a- alpha -propynyl-D-homo -4,9(10),16- estratriene-3-one (IC). Other antagonists (I) are known from EP 277676, EP 283428, EP 289073 and EP 311010.